We have a robust and growing intellectual property estate covering our mRNAi GOLD™ platform, including all aspects of siRNA modification, delivery, construct design, specific drug products and their uses.
As of March 2021, we solely owned 30 granted patents and have 106 pending patent applications. We expect our patent portfolio to continue to expand and mature over the next few years.